Brentuximab:治疗cd30阳性恶性肿瘤的重大进展

International Journal of Hematologic Oncology Pub Date : 2015-12-01 DOI:10.2217/IJH.15.27

P. Amarapurkar, J. Rosenblatt, D. Pereira

{"title":"Brentuximab:治疗cd30阳性恶性肿瘤的重大进展","authors":"P. Amarapurkar, J. Rosenblatt, D. Pereira","doi":"10.2217/IJH.15.27","DOIUrl":null,"url":null,"abstract":"Antibody-directed therapies allow greater selectivity in targeting of tumor associated antigens and spare normal cells. Brentuximab vedotin is an anti-CD30 antibody–drug conjugate. It has demonstrated impressive activity in the treatment of refractory and or relapsed Hodgkin's lymphoma, anaplastic large cell lymphoma and other CD30+ lymphoid malignancies. Several ongoing trials are testing the potential use of brentuximab vedotin for treatment of various CD30+ and CD30- malignancies in the setting of high-risk untreated disease. It is being tested in combination with chemotherapy, and testing in combination with immune therapy is also planned. CD30 plays a pivotal role in immune regulation and is also an attractive new target for intervention in the setting of select auto-immune diseases, as well as graft versus host disease.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"9 1","pages":"219-232"},"PeriodicalIF":0.0000,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.27","citationCount":"2","resultStr":"{\"title\":\"Brentuximab: a major advance in treatment of CD30-positive malignancies\",\"authors\":\"P. Amarapurkar, J. Rosenblatt, D. Pereira\",\"doi\":\"10.2217/IJH.15.27\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Antibody-directed therapies allow greater selectivity in targeting of tumor associated antigens and spare normal cells. Brentuximab vedotin is an anti-CD30 antibody–drug conjugate. It has demonstrated impressive activity in the treatment of refractory and or relapsed Hodgkin's lymphoma, anaplastic large cell lymphoma and other CD30+ lymphoid malignancies. Several ongoing trials are testing the potential use of brentuximab vedotin for treatment of various CD30+ and CD30- malignancies in the setting of high-risk untreated disease. It is being tested in combination with chemotherapy, and testing in combination with immune therapy is also planned. CD30 plays a pivotal role in immune regulation and is also an attractive new target for intervention in the setting of select auto-immune diseases, as well as graft versus host disease.\",\"PeriodicalId\":14166,\"journal\":{\"name\":\"International Journal of Hematologic Oncology\",\"volume\":\"9 1\",\"pages\":\"219-232\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/IJH.15.27\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hematologic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/IJH.15.27\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/IJH.15.27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

摘要

抗体导向疗法允许更大的选择性靶向肿瘤相关抗原和备用正常细胞。Brentuximab vedotin是一种抗cd30抗体-药物偶联物。它在治疗难治性和复发性霍奇金淋巴瘤、间变性大细胞淋巴瘤和其他CD30+淋巴样恶性肿瘤方面显示出令人印象深刻的活性。一些正在进行的试验正在测试brentuximab vedotin在高风险未治疗疾病中治疗各种CD30+和CD30-恶性肿瘤的潜在用途。它正在与化疗联合进行测试，也计划与免疫疗法联合进行测试。CD30在免疫调节中起着关键作用，也是干预某些自身免疫性疾病和移植物抗宿主病的一个有吸引力的新靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Brentuximab: a major advance in treatment of CD30-positive malignancies

Antibody-directed therapies allow greater selectivity in targeting of tumor associated antigens and spare normal cells. Brentuximab vedotin is an anti-CD30 antibody–drug conjugate. It has demonstrated impressive activity in the treatment of refractory and or relapsed Hodgkin's lymphoma, anaplastic large cell lymphoma and other CD30+ lymphoid malignancies. Several ongoing trials are testing the potential use of brentuximab vedotin for treatment of various CD30+ and CD30- malignancies in the setting of high-risk untreated disease. It is being tested in combination with chemotherapy, and testing in combination with immune therapy is also planned. CD30 plays a pivotal role in immune regulation and is also an attractive new target for intervention in the setting of select auto-immune diseases, as well as graft versus host disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Hematologic Oncology

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.